ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution
Over the past decade, we have seen a significant change in modern approaches in the first-line treatment of chronic lymphocytic leukemia (CLL). The CLL-10 study data established the FCR regimen as the treatment of choice for younger patients with limited comorbidities, while for patients older than...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
IP Habib O.N.
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/67aed2307be24cdebf0808eebbc30d52 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:67aed2307be24cdebf0808eebbc30d52 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:67aed2307be24cdebf0808eebbc30d522021-11-30T17:03:34ZELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution1815-14341815-144210.26442/18151434.2020.1.200090https://doaj.org/article/67aed2307be24cdebf0808eebbc30d522020-05-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/34167/22581https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Over the past decade, we have seen a significant change in modern approaches in the first-line treatment of chronic lymphocytic leukemia (CLL). The CLL-10 study data established the FCR regimen as the treatment of choice for younger patients with limited comorbidities, while for patients older than 65 years, the BR regimen is more often considered as less toxic one. According to published data, 46% of patients with newly diagnosed CLL have comorbidities. Moreover, high-risk patients with del(17p) and/or TP53 mutation do not have response on immunochemotherapy (ICT) most often. Thus, about 1/2 of the patients cannot be treated or will not respond to standard ICT regimens. Targeted therapy with Brutons tyrosine kinase (BTK) inhibitors is an important option of the first-line treatment of patients with CLL. Acalabrutinib is a highly selective second-generation BTK inhibitor that does not inhibit EGFR, ITK or TEC targets. Acalabrutinib in combination with obinutuzumab or as monotherapy can be considered as a highly effective and safe option of the first line of CLL therapy. Based on the hight selectivity of the agent, acalabrutinib can be considered as the preferable option for patients who are not eligible for ICT, including patients with commodities, such as cardiovascular diseases or risk factors for their development.Irina V. PoddubnayaLyubov S. Al-RadiTatyana E. ByalikKamil D. KaplanovValentina Z. MolostvovaEvgeniy A. NikitinTatyana I. PospelovaVadim V. PtushkinOlga S. SamoilovaElena A. StadnikGayane S. TumyanIP Habib O.N.articlechronic lymphocytic leukemiabruton’s tyrosine kinase inhibitorsimmunochemotherapytargeted therapyacalabrutinibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 1, Pp 31-33 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU |
| topic |
chronic lymphocytic leukemia bruton’s tyrosine kinase inhibitors immunochemotherapy targeted therapy acalabrutinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
chronic lymphocytic leukemia bruton’s tyrosine kinase inhibitors immunochemotherapy targeted therapy acalabrutinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Irina V. Poddubnaya Lyubov S. Al-Radi Tatyana E. Byalik Kamil D. Kaplanov Valentina Z. Molostvova Evgeniy A. Nikitin Tatyana I. Pospelova Vadim V. Ptushkin Olga S. Samoilova Elena A. Stadnik Gayane S. Tumyan ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution |
| description |
Over the past decade, we have seen a significant change in modern approaches in the first-line treatment of chronic lymphocytic leukemia (CLL). The CLL-10 study data established the FCR regimen as the treatment of choice for younger patients with limited comorbidities, while for patients older than 65 years, the BR regimen is more often considered as less toxic one. According to published data, 46% of patients with newly diagnosed CLL have comorbidities. Moreover, high-risk patients with del(17p) and/or TP53 mutation do not have response on immunochemotherapy (ICT) most often. Thus, about 1/2 of the patients cannot be treated or will not respond to standard ICT regimens. Targeted therapy with Brutons tyrosine kinase (BTK) inhibitors is an important option of the first-line treatment of patients with CLL. Acalabrutinib is a highly selective second-generation BTK inhibitor that does not inhibit EGFR, ITK or TEC targets. Acalabrutinib in combination with obinutuzumab or as monotherapy can be considered as a highly effective and safe option of the first line of CLL therapy. Based on the hight selectivity of the agent, acalabrutinib can be considered as the preferable option for patients who are not eligible for ICT, including patients with commodities, such as cardiovascular diseases or risk factors for their development. |
| format |
article |
| author |
Irina V. Poddubnaya Lyubov S. Al-Radi Tatyana E. Byalik Kamil D. Kaplanov Valentina Z. Molostvova Evgeniy A. Nikitin Tatyana I. Pospelova Vadim V. Ptushkin Olga S. Samoilova Elena A. Stadnik Gayane S. Tumyan |
| author_facet |
Irina V. Poddubnaya Lyubov S. Al-Radi Tatyana E. Byalik Kamil D. Kaplanov Valentina Z. Molostvova Evgeniy A. Nikitin Tatyana I. Pospelova Vadim V. Ptushkin Olga S. Samoilova Elena A. Stadnik Gayane S. Tumyan |
| author_sort |
Irina V. Poddubnaya |
| title |
ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution |
| title_short |
ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution |
| title_full |
ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution |
| title_fullStr |
ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution |
| title_full_unstemmed |
ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution |
| title_sort |
elevate-tn study. new data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. resolution |
| publisher |
IP Habib O.N. |
| publishDate |
2020 |
| url |
https://doaj.org/article/67aed2307be24cdebf0808eebbc30d52 |
| work_keys_str_mv |
AT irinavpoddubnaya elevatetnstudynewdataofacalabrutinibinfirstlinetreatmentofchroniclymphocyticleukemiaresolution AT lyubovsalradi elevatetnstudynewdataofacalabrutinibinfirstlinetreatmentofchroniclymphocyticleukemiaresolution AT tatyanaebyalik elevatetnstudynewdataofacalabrutinibinfirstlinetreatmentofchroniclymphocyticleukemiaresolution AT kamildkaplanov elevatetnstudynewdataofacalabrutinibinfirstlinetreatmentofchroniclymphocyticleukemiaresolution AT valentinazmolostvova elevatetnstudynewdataofacalabrutinibinfirstlinetreatmentofchroniclymphocyticleukemiaresolution AT evgeniyanikitin elevatetnstudynewdataofacalabrutinibinfirstlinetreatmentofchroniclymphocyticleukemiaresolution AT tatyanaipospelova elevatetnstudynewdataofacalabrutinibinfirstlinetreatmentofchroniclymphocyticleukemiaresolution AT vadimvptushkin elevatetnstudynewdataofacalabrutinibinfirstlinetreatmentofchroniclymphocyticleukemiaresolution AT olgassamoilova elevatetnstudynewdataofacalabrutinibinfirstlinetreatmentofchroniclymphocyticleukemiaresolution AT elenaastadnik elevatetnstudynewdataofacalabrutinibinfirstlinetreatmentofchroniclymphocyticleukemiaresolution AT gayanestumyan elevatetnstudynewdataofacalabrutinibinfirstlinetreatmentofchroniclymphocyticleukemiaresolution |
| _version_ |
1718406384338337792 |